Dianthus Therapeutics, Inc. (MGTA) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Syndax Pharmaceuticals, Inc.

Deciphera Pharmaceuticals, Inc.

Prime Medicine, Inc.

Relay Therapeutics, Inc.

Dianthus Therapeutics, Inc.

Protagonist Therapeutics, Inc.

Immatics NV

Cogent Biosciences, Inc.

Rayzebio, Inc.

Replimune Group, Inc.

Pliant Therapeutics, Inc.

Why is Dianthus Therapeutics, Inc. ?

The company has declared negative results for the last 3 consecutive quarters

NET SALES(HY) At USD 0.59 MM has Grown at -85.4%
OPERATING CASH FLOW(Y) Lowest at USD -109.52 MM
DEBT-EQUITY RATIO (HY) Highest at -73.44 %

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of 306.98%, its profits have fallen by -88.3%

Reducing Promoter Confidence

Promoters have decreased their stake in the company by -5.22% over the previous quarter and currently hold 14.46% of the company
Promoters decreasing their stake may signify reduced confidence in the future of the business

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Dianthus Therapeutics, Inc. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Dianthus Therapeutics, Inc.

304.69%

3.79

71.11%

S&P 500

13.68%

0.84

19.28%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

32.47%

EBIT Growth (5y)

-19.65%

EBIT to Interest (avg)

-79.28

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.80

Sales to Capital Employed (avg)

0.01

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

6.35

EV to EBIT

-21.85

EV to EBITDA

-21.92

EV to Capital Employed

21.29

EV to Sales

996.21

PEG Ratio

Dividend Yield

ROCE (Latest)

-97.40%

ROE (Latest)

-23.12%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

Bearish

Bollinger Bands

Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Dow Theory

Mildly Bearish

Mildly Bullish

OBV

No Trend

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

3What is working for the Company

NET PROFIT(HY)

Higher at USD -68.39 MM

CASH AND EQV(HY)

Highest at USD 660 MM

-32What is not working for the Company

NET SALES(HY)

At USD 0.59 MM has Grown at -85.4%

OPERATING CASH FLOW(Y)

Lowest at USD -109.52 MM

DEBT-EQUITY RATIO (HY)

Highest at -73.44 %

OPERATING PROFIT(Q)

Lowest at USD -40.19 MM

PRE-TAX PROFIT(Q)

Lowest at USD -36.77 MM

NET PROFIT(Q)

Lowest at USD -36.77 MM

RAW MATERIAL COST(Y)

Grown by 20.99% (YoY

DEBTORS TURNOVER RATIO(HY)

Lowest at 0.8 times

EPS(Q)

Lowest at USD -0.97

Here's what is working for Dianthus Therapeutics, Inc.

Cash and Eqv

Highest at USD 660 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is improving

Cash and Cash Equivalents

Here's what is not working for Dianthus Therapeutics, Inc.

Net Sales

At USD 0.59 MM has Grown at -85.4%

Year on Year (YoY)

MOJO Watch

Near term sales trend is very negative

Net Sales (USD MM)

Operating Cash Flow

Lowest at USD -109.52 MM and Fallen

In each year in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (USD MM)

Operating Profit

Lowest at USD -40.19 MM and Fallen

In each period in the last five periods

MOJO Watch

Near term Operating Profit trend is quite negative

Operating Profit (USD MM)

Pre-Tax Profit

Lowest at USD -36.77 MM and Fallen

In each period in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (USD MM)

Net Profit

Lowest at USD -36.77 MM and Fallen

In each period in the last five periods

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (USD MM)

Debt-Equity Ratio

Highest at -73.44 % and Grown

In each half year in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Pre-Tax Profit

At USD -36.77 MM has Fallen at -28.15%

over average net sales of the previous four periods of USD -28.69 MM

MOJO Watch

Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (USD MM)

Net Profit

At USD -36.77 MM has Fallen at -28.15%

over average net sales of the previous four periods of USD -28.69 MM

MOJO Watch

Near term Net Profit trend is negative

Net Profit (USD MM)

EPS

Lowest at USD -0.97

in the last five periods

MOJO Watch

Declining profitability; company has created lower earnings for shareholders

EPS (USD)

Debtors Turnover Ratio

Lowest at 0.8 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling Debtors has slowed

Debtors Turnover Ratio

Raw Material Cost

Grown by 20.99% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales